 ENGLEWOOD, CO ACCESSWIRE January 14, 2021 Viveve Medical, Inc. Viveve NASDAQ:VIVE, a medical technology company focused on womens intimate health, today announced the pricing of an upsized underwritten public offering of units for gross proceeds of approximately 24 Million or 27.6 million if the underwriters exercise their option to purchase additional shares prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve. The offering is comprised of 1 4,607,940 Class A Units, priced at a public offering price of 3.40 per Class A Unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an exercise price of 3.40 per share that expires on the fifth anniversary of the date of issuance, and 2 2,450,880 Class B Units, priced at a public offering price of 3.40 per Class B Unit, with each unit consisting of one share of Series C convertible preferred stock and one warrant to purchase one share of common stock, at an exercise price of 3.40 per share that expires on the fifth anniversary of the date of issuance. 